Management
Professor Ian Sanne [Division Head, Co-Founder]
Ian Sanne is a co-founder and Division Head of HE²RO. He is has a faculty appointment at the University of Witwatersrand as well as being a founder and managing director of Right to Care and the Clinical HIV Research Unit. He is leading specialist phyiscian in the field of HIV research who recently was elected as International Vice-Chair of the AIDS Clinical Trials Group. His research focuses on providing observational and prospective research to inform prevention and treatment strategies in the resource poor setting, with scientific contributions in the optimisation of treatment strategies, improved diagnostics and public health interventions for HIV and Tuberculosis in over 100 publications. At the intersection of clinical care, and clinical trial administration, Ian Sanne will offer his expertise from his experience as the founding Director and Chief Executive Officer of Right to Care, a large PEPFAR and Global Fund supported non-profit organisation. Ian Sanne has served in a number of leadership roles, both in research and implementation of clinical treatment services. Ian Sanne has led the Wits HIV Research Group since 2003 as CTU Principal Investigator.
Projects
-
Analysing the Impact and Cost of Scaling up Xpert MTB/RIF Technology for TB Diagnosis: The National TB Cost Model (NTCM)
In the South African context, smear microscopy and other conventional TB diagnostic technologies that have been used for decades, are no longer reliable, because many HIV-positive tuberculosis patients are smear-negative, and the long time to diagnosis means that many patients die without having started TB treatment. In December 2010 the GeneXpert System using the Xpert MTB/RIF assay received a strong recommendation from the World Health Organization as the initial test in individuals with HIV -
Investigating the Feasibility of Implementation of Multi-Disciplinary Point-of-Care Testing in an HIV Treatment Clinic Using a Randomised Controlled Trial
A major challenge to successful implementation of both antiretroviral and anti-tuberculosis therapy in low-resource settings remains the ability to diagnose and monitor the progress of both infections, a process that is hampered by lack of laboratory infrastructure, technical skill and poor integration of HIV and TB services. Recent technological innovations in the Point of Care (POC) testing arena promises to alleviate the problem by providing access to on-site laboratory tests with the future -
Rapid Initiation of Antiretroviral Treatment (RapIT) for Pregnant Women
Alongside the primary RapIT study, we are enrolling pregnant women at a public clinic in Johannesburg in a prospective study of the impact of the guidelines on retention on ART for the duration of pregnancy. We are comparing our main outcome, adherence to ART until delivery, for these women to a retrospective comparison group who received PMTCT under earlier -
RapIT: Rapid Initiation of Antiretroviral Therapy to Promote Early HIV/AIDS Treatment in South Africa
The RapIT study was a randomized strategy evaluation of the feasibility, effectiveness, and cost-effectiveness of rapid ART initiation using accelerated clinic procedures and point-of-care laboratory tests. Outpatient, non-pregnant, HIV-positive adults who came to two South African clinics for an HIV test or CD4 count, consented to study participation, and were eligible for ART under 2010 guidelines were randomized 1:1 to rapid ART initiation or to standard care. Those who were assigned to
Publications
-
Regimen durability in HIV-infected children and adolescents initiating first-line antiretroviral therapy in a large public sector HIV cohort in South Africa
-
Tenofovir stock shortages have limited impact on clinic-and patient-level HIV treatment outcomes in public sector clinics in South Africa
-
The right combination – treatment outcomes among HIV-positive patients initiating first-line fixed-dose antiretroviral therapy in a public sector HIV clinic in Johannesburg, South Africa
-
Cohort profile: the Right to Care Clinical HIV Cohort, South Africa
-
The High Cost of HIV-Positive Inpatient Care at an Urban Hospital in Johannesburg, South Africa
-
A predictive risk model for first line treatment failure in South Africa
-
Delaying second line antiretroviral therapy after first line failiure in South Africa: Moderating effect of CD4 count
-
Severe Adverse Events in Outpatient Drug-Resistant TB Treatment in South Africa
-
Rapid antiretroviral therapy initiation reduces attrition between HIV testing and treatment in Africa
-
The relation between efavirenz versus nevirapine and virologic failure in Johannesburg, South Africa
-
Attrition through Multiple Stages of HIV Care in South Africa
-
CD4 monitoring improves the sensitivity of a clinical algorithm developed to identify virological failure in HIV-positive patients on first-line antiretroviral therapy
-
Does most early mortality in patients on ART occur in care or lost to follow-up? Evidence from the Themba Lethu Clinic, South Africa
-
Impacts of disaggregating programmatic outcomes by documentation of citizenship in South Africa
-
Disaggregating programmatic outcomes by documentation of citizenship in South Africa
-
Predictive and prognostic properties of TB-LAM among HIV-positive patients initiating ART in Johannesburg, South Africa
-
Decrease in Single-drug Substitutions in the First 24-months on First-line Treatment amongst HIV-positive Children and Adolescents in South Africa
-
24-month Treatment Outcomes Amongst HIV-Positive Children and Adolescent Patients Prescribed Stavudine vs. Abacavir
-
Long-term outcomes of over one thousand patients on second-line antiretroviral therapy in South Africa
-
Eight years experience with attrition and mortality on antiretroviral therapy in South Africa
-
Second line failure and protease inhibitor resistance in a clinic in Johannesburg, South Africa
-
Predictors of Time to Switch to Second Line ART after First Line Failure in Johannesburg, South Africa
-
Risk Factors Associated with TB in Children Receiving ART in a South African Multicenter HIV Cohort
-
Obesity or hypertension at ART initiation and outcomes amongst HIV patients in South Africa
-
Predictors of incident hypertension in HIV-positive adults over 24 months on ART in South Africa
-
Changing the South African HIV and TB guidelines: The role of cost modelling
-
Costs of inpatient treatment for multi-drug resistant TB in South Africa
-
Estimating the Benefits of Treatment: The Patient Economic Outcomes Study
-
Anemia among HIV-Infected Patients Initiating Antiretroviral Therapy in South Africa: Improvement in Hemoglobin regardless of Degree of Immunosuppression and the Initiating ART Regimen
-
The Relation Between Efavirenz. vs. Nevirapine and Virologic Failure in Johannesburg, South Africa
-
Impact of nutritional supplementation on immune response, body mass index and bioimpedance in HIV-positive patients starting antiretroviral therapy (NuStART)
-
Current CD4 Count, More than Baseline, Predicts Loss to Follow-up from HIV Care
-
Same-Day CD4 Testing to Improve Uptake of HIV Care and Treatment in South Africa: Point-of-Care Is Not Enough
-
Antiretroviral treatment outcomes after the introduction of tenofovir in the public-sector in South Africa
-
Risk of Mortality and Loss to Follow-up amongst HIV-Positive Patients Prescribed Stavudine vs. Tenofovir: A matched cohort analysis
-
Incidence and Risk Factors Associated with Tuberculosis in HIV-positive Children Receiving Antiretroviral Therapy in a Large South African Multicenter Cohort
-
Decrease in Single Drug Substitutions in the First 12-months on First-line Treatment amongst HIV-positive Patients in Johannesburg, South Africa
-
Incidence of Herpes Zoster among HIV-infected Patients on Antiretroviral Therapy in Johannesburg, South Africa – Who Should We Vaccinate?
-
Viremia Copy-years as a Measure of Viral Load Burden and Associated Mortality Risk among Antiretroviral Therapy Patients in Johannesburg, South Africa
-
The Effect of 30 vs. 40mg of Stavudine vs. Tenofovir on Treatment Outcomes amongst HIV-positive Patients in Johannesburg, South Africa
-
The impact of antiretroviral therapy on quality of life and economic outcomes for South African patients: five-year follow-up
-
The impact of antiretroviral therapy on quality of life and economic outcomes for South African patients: five-year follow-up
-
Incident pulmonary tuberculosis on antiretroviral therapy: seven years of experience at the Themba Lethu Clinic in Johannesburg, South Africa
-
CD4 criteria improves the sensitivity of a clinical algorithm developed to identify viral failure in HIV-positive patients on first-line antiretroviral therapy
-
Patient retention from HIV diagnosis through one year on antiretroviral therapy at a primary health clinic in Johannesburg, South Africa
-
Initiation of ART at higher CD4 counts under South Africa’s revised antiretroviral therapy guidelines results in improved patient outcomes
-
Diagnosing Xpert MTB/RIF negative TB suspects: Impact and cost of an alternative algorithm
-
What To Do with Xpert Negatives? The Cost of Alternative Diagnostic Algorithms for TB Suspects Who Are Xpert MTB Negative in a High HIV/MDR-TB Burden Setting
-
HIV treatment outcomes after seven years in a large public-sector HIV treatment program in Johannesburg, South Africa
-
HIV-related Burden on South African Hospitals in the Era of Large-scale Access to Antiretroviral Therapy
-
Short-term impacts of a change in ART initiation threshold for patients co-infected with TB in Johannesburg, South Africa
-
What to do with Xpert negatives? The cost of alternative diagnostic algorithms for TB suspects who are Xpert MTB negative in a high HIV/MDR-TB burden setting
-
Low rates of nucleoside reverse transcriptase inhibitor resistance in a well monitored cohort in South Africa on antiretroviral therapy